Literature DB >> 17060081

Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.

Petra J Berggren de Verdier1, Rajiv Kumar, Jan Adolfsson, Per Larsson, Ulf Norming, Erik Onelöv, Hans Wijkström, Gunnar Steineck, Kari Hemminki.   

Abstract

OBJECTIVE: The 9p21 locus is a major target in the pathogenesis of human urinary bladder cancer. This locus harbours the CDKN2A/ARF tumour suppressor gene, which encodes two cell-cycle regulatory proteins: p16INK4a and p14ARF. We studied how homozygous deletions and multiple duplications at this locus affect prognosis and survival in patients with bladder cancer.
MATERIAL AND METHODS: Real-time quantitative polymerase chain reaction (QPCR), based on simultaneous amplification of ARF and a reference gene, glyceraldehyde-3-phosphate dehydrogenase, was used to measure homozygous deletions and multiple duplications in a population-based material consisting of 478 patients with urinary bladder cancer. Results from real-time QPCR were compared with clinico-pathological parameters and survival curves were generated using the Kaplan-Meier method.
RESULTS: Real-time QPCR analysis showed 71 (15%) homozygous deletions and 8 (2%) multiple duplications. We were unable to find any association between either stage or grade and urinary neoplasms with homozygous deletions. However, although there were only a limited number of patients with multiple duplications, 7/8 of them had highly malignant tumours (G2b-G4 or > or = T1; p = 0.02).
CONCLUSIONS: Urinary bladder cancers constitute a spectrum of neoplasms with varying clinical manifestations. We were unable to establish a prognostic relevance for patients with tumours harbouring homozygous deletions at the CDKN2A/ARF locus. However, our data did indicate that patients with multiple duplications at the CDKN2A/ARF locus had poor survival. This suggests that multiple duplications, in combination with other genetic changes, have cooperative effects which have a negative outcome on urinary bladder cancer prognosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17060081     DOI: 10.1080/00365590600795396

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  5 in total

1.  ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.

Authors:  Tomasz B Owczarek; Takashi Kobayashi; Ricardo Ramirez; Lijie Rong; Anna M Puzio-Kuter; Gopa Iyer; Min Yuen Teo; Francisco Sánchez-Vega; Jingqiang Wang; Nikolaus Schultz; Tian Zheng; David B Solit; Hikmat A Al-Ahmadie; Cory Abate-Shen
Journal:  Cancer Res       Date:  2017-01-12       Impact factor: 12.701

Review 2.  Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.

Authors:  David W Chang; Jian Gu; Xifeng Wu
Journal:  Urol Oncol       Date:  2012 Jul-Aug       Impact factor: 3.498

3.  Auxiliary diagnostic value of p16 amplification combined with the detection of heterozygous and homozygous loss for urothelial carcinoma.

Authors:  Xiaopeng Mao; Baimou Li; Ying Liang; Shuhua Li; Jianwen Zhou; Qiong He; Neng Jiang; Yangshan Chen; Yu Sun; Yongmei Cui; Wenting Jiang; Han Wang; Liantang Wang; Zunfu Ke
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

4.  Significant Correlation between Chromosomal Aberration and Nuclear Morphology in Urothelial Carcinoma.

Authors:  Masayo Shuto; Atsushi Seyama; Yoshiya Gotoh; Kouichi Kamada; Masaru Nakamura; Kenji Warigaya; Hiroshi Watanabe; Munehisa Ueno; Michio Shimizu; Toshio Fukuda; Shin-Ichi Murata
Journal:  Acta Histochem Cytochem       Date:  2012-01-24       Impact factor: 1.938

5.  Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors.

Authors:  Michèle J Hoffmann; Judith Dehn; Johanna Droop; Günter Niegisch; Christian Niedworok; Tibor Szarvas; Wolfgang A Schulz
Journal:  Noncoding RNA       Date:  2015-12-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.